Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

0350402 - PSÚ 2011 RIV CH eng J - Journal Article
Smržová, J. - Urbánek, Tomáš
Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?
Kidney & Blood Pressure Research. Roč. 33, č. 5 (2010), s. 333-342. ISSN 1420-4096. E-ISSN 1423-0143
Institutional research plan: CEZ:AV0Z70250504
Keywords : Cinacalcet * Itching * Phosphate binders
Subject RIV: FE - Other Internal Medicine Disciplines
Impact factor: 1.500, year: 2010
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ArtikelNr=317935&Ausgabe=254503&ProduktNr=224258

The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, Ca×P, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 ± 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 ± 9.59 to 20.62 ± 9.22. Cinacalcet decreased elevated s-Ca, s-P, Ca×P, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT.
Permanent Link: http://hdl.handle.net/11104/0190417